Observational studyAging clinical and experimental research2025
Visuospatial impairment in dementia: a new index to improve the clinical diagnosis of Alzheimer's disease.
Observational study in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology of visuospatial impairment in older adults: the Harmonized Cognitive Assessment Protocol.Innovation in aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe differential diagnosis between Alzheimer's disease (AD) and other causes of dementia is essential but challenging. Therefore, there is an increasing need for early, reliable, and non-invasive tests to distinguish between different forms of dementia.
aimsTo determine whether neuropsychological tests assessing visuospatial function can improve confidence in the clinical diagnosis of AD.
methodsRetrospective observational single-center cohort study involving all patients consecutively referred to our outpatient clinic for cognitive disorders who underwent neuropsychological assessment between 2013 and 2018. In addition to demographic and functional variables, each patient underwent neuropsychological tests to assess cognitive performance, memory, and executive, language, and visuospatial ability, according to clinical protocols. The clinical diagnosis of cognitive disorders, based on standard diagnostic criteria, served as the gold standard. Accuracy measures of visuospatial tests to diagnose AD were calculated. Additionally, a new index derived from the sum of four items (Rey-Osterrieth figure copying, Copy of Drawings, Clock Drawing Test, and years of schooling) was tested (ReDCOOL).
resultsOf the 342 patients analyzed, 308 were diagnosed with dementia or mild cognitive impairment, including 60 with AD. AD patients exhibited the worst performance in visuospatial tests, and the utilization of the ReDCOOL index proved to be more dependable in identifying AD compared to other tests (AUROC 0.729, 95%CI 0.659-0.799; p < 0.001).
conclusionThe ReDCOOL index appears to increase confidence in the clinical diagnosis of AD compared to each of the visuospatial tests considered. Furthermore, this index is easily calculated and does not prolong the time needed for clinical evaluation, as it does not require a customized patient assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.